Overview

Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia

Status:
NOT_YET_RECRUITING
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
Evaluate the safety and tolerance of multiple subcutaneous injections of SHR-2173 in ITP patients
Phase:
PHASE1
Details
Lead Sponsor:
Guangdong Hengrui Pharmaceutical Co., Ltd